November 3, 2015Open Access

Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness

TDThibaud DamyHeart Failure & Transplant BCBruno CostesInserm AHAlbert HagègeHeart Failure & Transplant

Structured PICO

Population

Patients diagnosed with hypertrophic cardiomyopathy or increased left ventricular wall thickness

Outcome

Prevalence of hereditary transthyretin amyloid cardiomyopathy (mTTR-FAC)

Genetic screening for mutated transthyretin is warranted in elderly patients with increased left ventricular wall thickness, as 5% of patients diagnosed with hypertrophic cardiomyopathy actually have mTTR-FAC.

Abstract

Five per cent of patients diagnosed with hypertrophic cardiomyopathy have mTTR-FAC. Mutated transthyretin genetic screening is warranted in elderly subjects with increased LVWT, particularly, those of African descent with neuropathy, carpal tunnel syndrome, ECG low voltage, or LGE.

Perguntar à IA

Bookmark

View Full Paper